Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolerability data with vamorolone in Duchenne muscular dystrophy ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 ...
Pratteln, Switzerland, February 18, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces full redemption of its senior unsecured convertible bonds (the 2017/22 Bonds, ISIN CH0353955195), effective February 17, 2022. The repayment reduces convertible ...
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 24, 2021 – Santhera Pharmaceuticals (SIX: SANN) provides an update on its activities and is calling an Extraordinary General ...
Ad hoc announcement pursuant to Art. 53 LR Vamorolone given throughout the study showed sustained efficacy across multiple endpoints over 48 weeks and the good safety and tolerability profile was ...
Ad hoc announcement pursuant to Art. 53 LR Cash and cash equivalents of CHF 8.0 million (as of June 30, 2021)Net revenue CHF 4.5 million (H1-2020: CHF 7.8 million)Net result for period of CHF -20.5 ...
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, October 1, 2021 : SIX Exchange Regulation has permitted Santhera to publish its interim report for the six-month period ended June ...
Copyright © 2015 - 2021 Lifecarenews.in
